Cargando…
Challenges in mass drug administration for treating lymphatic filariasis in Papua, Indonesia
BACKGROUND: The World Health Organization (WHO) Global Program to Eliminate Lymphatic Filariasis relies on mass drug administration (MDA) of two drugs annually for 4 to 6 years. The goal is to reduce the reservoir of microfilariae in the blood to a level insufficient to maintain transmission by the...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2928210/ https://www.ncbi.nlm.nih.gov/pubmed/20701744 http://dx.doi.org/10.1186/1756-3305-3-70 |
_version_ | 1782185838154612736 |
---|---|
author | Bhullar, Navneet Maikere, Jacob |
author_facet | Bhullar, Navneet Maikere, Jacob |
author_sort | Bhullar, Navneet |
collection | PubMed |
description | BACKGROUND: The World Health Organization (WHO) Global Program to Eliminate Lymphatic Filariasis relies on mass drug administration (MDA) of two drugs annually for 4 to 6 years. The goal is to reduce the reservoir of microfilariae in the blood to a level insufficient to maintain transmission by the mosquito vector. In 2008, the international medical aid organization Médecins Sans Frontières (MSF) performed the first round of a MDA in the high-burden area of Asmat district, in Papua, Indonesia. We report the challenges faced in this MDA on a remote Indonesian island and propose solutions to overcome these hurdles in similar future contexts. RESULTS: During the MDA, we encountered difficult challenges in accessing as well as persuading the patient population to take the antifilarial drugs. Health promotion activities supporting treatment need to be adapted and repetitive, with adequate time and resources allocated for accessing and communicating with local, seminomadic populations. Distribution of bednets resulted in an increase in MDA coverage, but it was still below the 80-85% target. CONCLUSIONS: MDA for lymphatic filariasis is how the WHO has planned to eliminate the disease from endemic areas. Our programmatic experience will hopefully help inform future campaign planning in difficult-to-access, high-burden areas of the world to achieve target MDA coverage for elimination of lymphatic filariasis. |
format | Text |
id | pubmed-2928210 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-29282102010-08-26 Challenges in mass drug administration for treating lymphatic filariasis in Papua, Indonesia Bhullar, Navneet Maikere, Jacob Parasit Vectors Research BACKGROUND: The World Health Organization (WHO) Global Program to Eliminate Lymphatic Filariasis relies on mass drug administration (MDA) of two drugs annually for 4 to 6 years. The goal is to reduce the reservoir of microfilariae in the blood to a level insufficient to maintain transmission by the mosquito vector. In 2008, the international medical aid organization Médecins Sans Frontières (MSF) performed the first round of a MDA in the high-burden area of Asmat district, in Papua, Indonesia. We report the challenges faced in this MDA on a remote Indonesian island and propose solutions to overcome these hurdles in similar future contexts. RESULTS: During the MDA, we encountered difficult challenges in accessing as well as persuading the patient population to take the antifilarial drugs. Health promotion activities supporting treatment need to be adapted and repetitive, with adequate time and resources allocated for accessing and communicating with local, seminomadic populations. Distribution of bednets resulted in an increase in MDA coverage, but it was still below the 80-85% target. CONCLUSIONS: MDA for lymphatic filariasis is how the WHO has planned to eliminate the disease from endemic areas. Our programmatic experience will hopefully help inform future campaign planning in difficult-to-access, high-burden areas of the world to achieve target MDA coverage for elimination of lymphatic filariasis. BioMed Central 2010-08-11 /pmc/articles/PMC2928210/ /pubmed/20701744 http://dx.doi.org/10.1186/1756-3305-3-70 Text en Copyright ©2010 Bhullar and Maikere; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Bhullar, Navneet Maikere, Jacob Challenges in mass drug administration for treating lymphatic filariasis in Papua, Indonesia |
title | Challenges in mass drug administration for treating lymphatic filariasis in Papua, Indonesia |
title_full | Challenges in mass drug administration for treating lymphatic filariasis in Papua, Indonesia |
title_fullStr | Challenges in mass drug administration for treating lymphatic filariasis in Papua, Indonesia |
title_full_unstemmed | Challenges in mass drug administration for treating lymphatic filariasis in Papua, Indonesia |
title_short | Challenges in mass drug administration for treating lymphatic filariasis in Papua, Indonesia |
title_sort | challenges in mass drug administration for treating lymphatic filariasis in papua, indonesia |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2928210/ https://www.ncbi.nlm.nih.gov/pubmed/20701744 http://dx.doi.org/10.1186/1756-3305-3-70 |
work_keys_str_mv | AT bhullarnavneet challengesinmassdrugadministrationfortreatinglymphaticfilariasisinpapuaindonesia AT maikerejacob challengesinmassdrugadministrationfortreatinglymphaticfilariasisinpapuaindonesia |